Buy
Sell
Share Name Share Symbol Market Type Share ISIN Share Description
Ip Group Plc LSE:IPO London Ordinary Share GB00B128J450 ORD 2P
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  -0.50 -0.57% 87.00 85.60 85.90 88.00 85.00 87.50 3,974,773 16:35:28
Industry Sector Turnover (m) Profit (m) EPS - Basic PE Ratio Market Cap (m)
General Financial 0.0 -78.8 -7.1 - 924

Ip Share Discussion Threads

Showing 2001 to 2021 of 2150 messages
Chat Pages: 86  85  84  83  82  81  80  79  78  77  76  75  Older
DateSubjectAuthorDiscuss
07/10/2020
06:37
IP Group plc - Portfolio company Enterprise Therapeutics' TMEM16A potentiator program for treatment of cystic fibrosis & other respiratory diseases acquired by Roche -- IP Group's cash realisations for the year now total GBP183.9m IP Group plc (LSE: IPO) ("IP Group" or "the Group"), the developer of intellectual property-based businesses, is delighted to note that portfolio company Enterprise Therapeutics Ltd ("Enterprise" or "the Company") has announced that its novel TMEM16A potentiator portfolio has been acquired by Roche and will be developed by Genentech, a member of the Roche Group. In connection with the transaction, Enterprise's shareholders received an upfront payment of GBP75 million, and are eligible to receive additional contingent payments, to be made based on the achievement of certain predetermined milestones. As a result of this transaction, IP Group's cash realisations for the year to date now total GBP183.9 million, 2.3 times greater than the GBP79.5 million recorded for the whole of 2019. Following completion of the transaction, the Group has an undiluted beneficial shareholding of 21.7% in Enterprise. At 30 June 2020, the Group's shareholding in Enterprise was valued at GBP9.0 million. The Group's directors anticipate the transaction will result in a fair value gain and are currently reviewing the carrying value of Enterprise, which will be confirmed no later than the 2020 Annual Results. Enterprise is a biopharmaceutical company dedicated to the discovery and development of novel therapies to improve the lives of patients suffering with respiratory disease. The TMEM16A portfolio includes ETD002, which recently entered Phase 1 trials, and is focused toward treating all people with cystic fibrosis (CF) with potential to benefit people with other severe respiratory diseases characterised by excessive mucus congestion. Following acquisition of the TMEM16A portfolio, Enterprise will continue to develop its remaining lead respiratory program, the ENaC blocker ETD001.
bamboo2
06/10/2020
07:24
Good chance you are right bambooo.
p1nkfish
06/10/2020
06:50
Still no holdings notice for the 60m [in addition to the more usual volume] or so shares [approx 6%] that were traded recently. Since we heard no more about Tencent buying ONT from Invesco, I reckon it might be them accumulating.
bamboo2
01/10/2020
13:11
Bed side testing too. Actual Experience received chance to be used with Oracle.
p1nkfish
01/10/2020
12:50
When it is released, it will be possible to connect up the new Smidgion device to any smartphone using the Genopo software discussed in the post above. This will allow reliable personal testing for CV19 giving lab quality results in under an hour. It is not then a great leap to allow personal testing for many other conditions and maladies. Results can be forwarded using the phone, for confirmation of diagnosis. Https://nanoporetech.com/products/smidgion
bamboo2
30/9/2020
16:38
Connecting an ONT MinION to a smartphone for portable DNA analysis. The advent of portable nanopore sequencing devices has enabled DNA and RNA sequencing to be performed in the field or the clinic. However, advances in in situ genomics require parallel development of portable, offline solutions for the computational analysis of sequencing data. Here we introduce Genopo, a mobile toolkit for nanopore sequencing analysis. Genopo compacts popular bioinformatics tools to an Android application, enabling fully portable computation. To demonstrate its utility for in situ genome analysis, we use Genopo to determine the complete genome sequence of the human coronavirus SARS-CoV-2 in nine patient isolates sequenced on a nanopore device, with Genopo executing this workflow in less than 30 min per sample on a range of popular smartphones. Https://www.nature.com/articles/s42003-020-01270-z
bamboo2
28/9/2020
15:10
I'll take a guess at news tomorrow. Dex, assuming you are still holding, you are now in profit! "Ip Group Plc hit an upwards yearly price breakout."
bamboo2
28/9/2020
08:18
There are a number of trials going on around the world using ONT gear for diagnostic testing. Andrew Beggs has been leading one in Birmingham that offers daily testing for frontline NHS staff. This is due to report imminently. Https://www.birminghamhealthpartners.co.uk/bhp-upscaling-covid-19-testing-for-frontline-staff/
bamboo2
27/9/2020
14:27
Brucie 5 ...thank you
lasata
27/9/2020
13:57
lasata, re your post 571, here's what I hope may be a useful *tip*. Do take care about clicking on links of uncertain provenance. May I suggest you make a point of looking at the posters posts across the boards, and if as in this case you observe only repeated links to the same *TIP* you assume the worst and filter. I say this without any definitive knowledge about the poster. Except that he is putting this on many boards and you are probably best advised to steer well clear.
brucie5
27/9/2020
11:48
CarolPeters789 Please could you summarise what the "tip" says...as i cannot download it. Thank you
lasata
27/9/2020
08:57
Close above 82 and it looks likely to draw in more money imho. Dyor, etc.
p1nkfish
27/9/2020
08:52
I think the money is largely esr marked for some or other collection of moonshots. Taking out the forced seller can still be done and have a large pile left.
p1nkfish
27/9/2020
08:34
dex, I have written to management a few times and always got a reply within 24 hours, why don't you express your thoughts to them? With the cash, there are a lot of options, I'm sure that a dividend will have been considered, along with numerous other ideas. A middle road might be best of all, where the forced seller could be taken out, increase ONT if possible, and a special.
bamboo2
26/9/2020
20:48
I don't trust this management with the proceeds of sales. They just want to keep the salary gravy train rolling (obviously, why wouldn't they). Distributions to shareholders of any sale proceeds is the only sensible way forward....
dexdringle
26/9/2020
19:30
Money ear marked for new investments. Waiting.
p1nkfish
26/9/2020
19:06
p1nk, A deal with Invesco to buy back shares, along with Invesco's direct holding in ONT would be a good one. Makes me wonder if looking at the relevant Invesco funds is an idea? Or are the redemptions still a big problem?
bamboo2
26/9/2020
19:04
Thank you quite high volume in this share the last few days...wonder why?
lasata
26/9/2020
18:59
I mean where will it find a home? Have some suspicions.
p1nkfish
26/9/2020
18:32
lasata, the first link in the header is the results to 30/6/2020 It also refers to some post period end events. This will answer your question. Https://www.ipgroupplc.com/~/media/Files/I/IP-Group-V2/documents/investor-relations/ipg-hy20-results-presentation.pdf
bamboo2
26/9/2020
18:24
What cash?
lasata
Chat Pages: 86  85  84  83  82  81  80  79  78  77  76  75  Older
ADVFN Advertorial
Your Recent History
LSE
IPO
Ip
Register now to watch these stocks streaming on the ADVFN Monitor.

Monitor lets you view up to 110 of your favourite stocks at once and is completely free to use.

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

P: V: D:20201129 20:41:57